Trial reportThyroid : official journal of the American Thyroid Association2020
An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Open access · greenAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Thyroid : official journal of the American Thyroid Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2025Guideline
- A computational framework for optimizing radioiodine therapy protocols in metastatic thyroid cancer.Scientific reports · 2026Article
- Systemic Therapeutic Options in Radioiodine-Refractory Differentiated Thyroid Cancer: Current Indications and Optimal Timing.Cancers · 2025Review
- High risk factors, molecular features and clinical management for radioactive iodine-refractory differentiated thyroid carcinoma.Frontiers in oncology · 2025Review
- Efficacy and Safety of Pazopanib in the Treatment of Thyroid Cancer: A Systematic Review.Biomedicines · 2024Review
- Systemic treatments for radioiodine-refractory thyroid cancers.Frontiers in endocrinology · 2024Review
- Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer.Life (Basel, Switzerland) · 2023Review
- Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer.Medical oncology (Northwood, London, England) · 2023Review
- Crosstalk between Thyroid Carcinoma and Tumor-Correlated Immune Cells in the Tumor Microenvironment.Cancers · 2023Review
- Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture.International journal of molecular sciences · 2023Article
- Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance.Frontiers in endocrinology · 2023Review
- Maternal iodine deficiency: a newborns' overweight risk factor? A prospective study.Archives of gynecology and obstetrics · 2022Article
- Article
- Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects.Frontiers in endocrinology · 2022Review
- Review
- Molecular-Driven Therapy in Advanced Thyroid Cancer.Current treatment options in oncology · 2021Review
- Case Report: Anlotinib Therapy in a Patient With Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAFFrontiers in oncology · 2021Article
- Advancements in the treatment of differentiated thyroid cancer.Therapeutic advances in endocrinology and metabolism · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 13 institutions in 4 countries.
Keith C BibleDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Michael E MenefeeDivision of Hematology and Oncology, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA.
Chia-Chi Josh LinDepartment of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Michael J MillwardDepartment of Medical Oncology, University of Western Australia, Perth, Australia.
William J MaplesDivision of Hematology and Oncology, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA.
Boon Cher GohDivision of Medical Oncology, National University Cancer Institute, Singapore, Singapore.
Nina J KarlinDivision of Hematology and Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona, USA.
Madeleine A KaneDepartment of Medical Oncology, University of Colorado, Denver, Colorado, USA.
Douglas R AdkinsDivision of Medical Oncology, Department of Medicine, Washington University, St. Louis, Missouri, USA.
Julian R MolinaDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Ross C DonehowerDivision of Medical Oncology, Department of Medicine, Johns Hopkins, Baltimore, Maryland, USA.
Wan-Teck LimDivision of Medical Oncology, National University Cancer Institute, Singapore, Singapore.
Patrick J FlynnMinnesota Oncology, Minneapolis, Minnesota, USA.
Ronald L RichardsonDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Anne M TraynorDivision of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA.
Joseph RubinDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Patricia M LoRussoDepartment of Oncology, Wayne State University, Detroit, Michigan, USA.
Robert C SmallridgeDivision of Hematology and Oncology, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA.
Jill K BurtonDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Vera J SumanDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Aditi KumarDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Jessie S VossDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Kandalaria M RumillaDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Benjamin R KippDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Ashish V ChintakuntlawarDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Pamela HarrisCancer Therapy Evaluation Program (CTEP), Bethesda, Maryland, USA.
Charles ErlichmanDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Mayo Clinic · USJacksonville College · USNational University Cancer Institute, Singapore · SGJohns Hopkins University · USMayo Clinic in Arizona · USMinnesota Oncology · USNational Cancer Institute · USNational Taiwan University Hospital · TWThe University of Western Australia · AUUniversity of Colorado Boulder · USUniversity of Wisconsin–Madison · USWashington University in St. Louis · USWayne State University · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MNCATS NIH HHS UL1 TR001863
Abstract
PubMed holds no abstract for this paper.
Indexed as
AgedAntibodiesBiomarkers, TumorCell DifferentiationDisease-Free SurvivalDisease ProgressionDNA Mutational AnalysisFemaleHumansIndazolesIodine RadioisotopesMaleMiddle AgedProgression-Free SurvivalProspective StudiesProtein Kinase InhibitorsAntibodiesBiomarkers, TumorIndazolesIodine RadioisotopespazopanibProtein Kinase InhibitorsPyrimidinesSulfonamidesThyroglobulindifferentiated thyroid cancerkinase inhibitorpazopanibradioactive iodine refractory
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.